Written by
in
Sonelokimab substantially improved signs and symptoms of psoriatic arthritis (PsA), meeting the primary endpoint of American College of Rheumatology (ACR) 50 response at week 12 compared to placebo in a phase 2 trial.1
“While IL-17A and IL-17F…
